This wiki has undergone a migration to Confluence found Here
Difference between revisions of "20140528 PLA call"
Jump to navigation
Jump to search
| Line 16: | Line 16: | ||
|- | |- | ||
| colspan="1" align="right"|'''Facilitator''' | | colspan="1" align="right"|'''Facilitator''' | ||
| − | | colspan="1" align="left"|Mary Kay | + | | colspan="1" align="left"|Mary Kay |
| colspan="1" align="right"|'''Note taker(s)''' | | colspan="1" align="right"|'''Note taker(s)''' | ||
| colspan="1" align="left"| Lynn | | colspan="1" align="left"| Lynn | ||
| Line 52: | Line 52: | ||
| || Tony Julian | | || Tony Julian | ||
|- | |- | ||
| − | | || Paul Knapp | + | | x|| Paul Knapp |
|- | |- | ||
| − | | || Austin Kreisler, | + | | x|| Austin Kreisler, |
|- | |- | ||
| − | | || Lynn Laakso | + | |x || Lynn Laakso |
|- | |- | ||
| − | | || Mary Kay McDaniel | + | |x || Mary Kay McDaniel |
|- | |- | ||
| − | | || | + | |x || Ken McCaslin |
|- | |- | ||
| || John Quinn | | || John Quinn | ||
|- | |- | ||
| − | | || John Roberts | + | |x || John Roberts |
|- | |- | ||
| regrets|| Andy Stechishin | | regrets|| Andy Stechishin | ||
| Line 102: | Line 102: | ||
===Minutes=== | ===Minutes=== | ||
| − | Convened | + | Convened when Lynn arrives (2:01 PM EDT) |
| + | *Agenda review | ||
| + | *Notes of [[20140507_HL7_PLA_Meeting]] review; Ken suggests we simply solicit comments on the last minutes. [http://gforge.hl7.org/gf/project/hlbam2b/scmsvn/?action=browse&path=%2Ftrunk%2Fdocuments%2F Links to BAM documents] helpful. | ||
| + | **A-ha moments | ||
| + | ***MaryKay had one that made clear what we were trying to accomplish. She thanks Austin for describing the efforts and providing the examples in the immunization registry work. | ||
| + | ***Ken had a better understanding as well. | ||
| + | *Project Services noticed we currently have 19 projects with “New Product Definition”. | ||
| + | **Any likely candidates for standards product family? Austin describes the subset of them may have an actual new product but we're looking for indicators of a new product family. Some project facilitators may have ticked the box on the PSS erroneously. Ken notes if the WG knows they have a new product family they need to socialize that with the PLA before they socialize the PSS. | ||
| + | **Austin cites the example of last fall's introduction of the vMR-CDS projects masquerading as V3. | ||
| + | **Product lines are not simply subsets of product families; they all address a consumer perspective with a use case for implementation as with the immunization use case (Project 863) with V2.x, services, and CDA all used to address all the requirements. Understanding needed of Product family, producer perspective, shared development methodology. | ||
| + | **A new type of artifact, or type of product is more what this box on the PSS has been used for; for example the EHR-S Functional Requirements for Laboratory Interoperability Transactions - EHR-S Func Reqs IG for LOI or LRI is defining a new type of IG or type of EHR-S FP as a new product/artifact. It's not a new product family. They're not an IG but instructions to an EHR on what to do with Lab Orders or Lab Results for interaction with the S&I Framework. Austin notes they do not constrain a standard but provide guidance and don't belong on the normative track but informative. | ||
| + | **May also want to practice describing a product family, e.g. V2 IGs working with a product family we already know before going through the list to identify new product families for which we would want to provide distinction between them and the product families already in existence. | ||
| + | **Harmonization of Health Quality Measures and vMR-CDS is another new product family (e.g. FHIR) along with Clinical Quality Expression Language (PI 1108). We already have Gello and Arden Syntax as other candidate expression languages. CQEL still needs to be reviewed by the US Realm Task Force. They did not tick the new product definition box. | ||
| + | *Next Steps - review an existing product family to formalize the definition | ||
| + | **Discuss which aspects of the BAM are well-enough defined to start defining a product family; operationalizing the BAM has been stymied with delays in its development by ARB. Austin suggests MaryKay join the ARB next Tuesday to find out where they are. MaryKay cannot make it but Ken may be able to on June 3rd. Austin may have jury duty. | ||
| + | **Push 2.x through that process. | ||
| + | *MaryKay will be out of pocket for next two weeks and unable to communicate. Lynn will be unavailable the 25th. The next PLA call will be July 9th. Communicate via the platf@lists.hl7.org in the meantime. | ||
| − | Adjourned | + | Adjourned 2:57 PM |
===Meeting Outcomes=== | ===Meeting Outcomes=== | ||
| Line 120: | Line 136: | ||
| width="100%" align="left" style="background:#f0f0f0;"|'''Actions''' '' | | width="100%" align="left" style="background:#f0f0f0;"|'''Actions''' '' | ||
| − | + | ||
|- | |- | ||
| Line 134: | Line 150: | ||
|width="100%" |'''Next Meeting/Preliminary Agenda Items'''<br/> | |width="100%" |'''Next Meeting/Preliminary Agenda Items'''<br/> | ||
| − | *[[ | + | *[[20140709 PLA call]] |
| − | + | *Follow up on the BAM and extrapolation discussion | |
|} | |} | ||
© 2014 Health Level Seven® International. All rights reserved | © 2014 Health Level Seven® International. All rights reserved | ||
Latest revision as of 18:58, 28 May 2014
return to HL7 Product Line Architecture Meeting Minutes and Agendas
Return to HL7 Product Line Architecture Program
| HL7 PLA Call Minutes Location: Phone: +1 770-657-9270, Participant Code: 985371, |
Date: 2014-05-28 Time: 2PM | ||
| Facilitator | Mary Kay | Note taker(s) | Lynn |
| Attendee | Name
| ||
| regrets | Calvin Beebe | ||
| Woody Beeler | |||
| Lorraine Constable | |||
| Bo Dagnall | |||
| Jean Duteau, | |||
| Rick Haddorff | |||
| Tony Julian | |||
| x | Paul Knapp | ||
| x | Austin Kreisler, | ||
| x | Lynn Laakso | ||
| x | Mary Kay McDaniel | ||
| x | Ken McCaslin | ||
| John Quinn | |||
| x | John Roberts | ||
| regrets | Andy Stechishin | ||
| no quorum definition | |||
Agenda
Agenda review
- Notes of 20140507_HL7_PLA_Meeting review
- A-ha moments
- Project Services noticed we currently have 19 projects with “New Product Definition”.
- Next Steps
Minutes
Convened when Lynn arrives (2:01 PM EDT)
- Agenda review
- Notes of 20140507_HL7_PLA_Meeting review; Ken suggests we simply solicit comments on the last minutes. Links to BAM documents helpful.
- A-ha moments
- MaryKay had one that made clear what we were trying to accomplish. She thanks Austin for describing the efforts and providing the examples in the immunization registry work.
- Ken had a better understanding as well.
- A-ha moments
- Project Services noticed we currently have 19 projects with “New Product Definition”.
- Any likely candidates for standards product family? Austin describes the subset of them may have an actual new product but we're looking for indicators of a new product family. Some project facilitators may have ticked the box on the PSS erroneously. Ken notes if the WG knows they have a new product family they need to socialize that with the PLA before they socialize the PSS.
- Austin cites the example of last fall's introduction of the vMR-CDS projects masquerading as V3.
- Product lines are not simply subsets of product families; they all address a consumer perspective with a use case for implementation as with the immunization use case (Project 863) with V2.x, services, and CDA all used to address all the requirements. Understanding needed of Product family, producer perspective, shared development methodology.
- A new type of artifact, or type of product is more what this box on the PSS has been used for; for example the EHR-S Functional Requirements for Laboratory Interoperability Transactions - EHR-S Func Reqs IG for LOI or LRI is defining a new type of IG or type of EHR-S FP as a new product/artifact. It's not a new product family. They're not an IG but instructions to an EHR on what to do with Lab Orders or Lab Results for interaction with the S&I Framework. Austin notes they do not constrain a standard but provide guidance and don't belong on the normative track but informative.
- May also want to practice describing a product family, e.g. V2 IGs working with a product family we already know before going through the list to identify new product families for which we would want to provide distinction between them and the product families already in existence.
- Harmonization of Health Quality Measures and vMR-CDS is another new product family (e.g. FHIR) along with Clinical Quality Expression Language (PI 1108). We already have Gello and Arden Syntax as other candidate expression languages. CQEL still needs to be reviewed by the US Realm Task Force. They did not tick the new product definition box.
- Next Steps - review an existing product family to formalize the definition
- Discuss which aspects of the BAM are well-enough defined to start defining a product family; operationalizing the BAM has been stymied with delays in its development by ARB. Austin suggests MaryKay join the ARB next Tuesday to find out where they are. MaryKay cannot make it but Ken may be able to on June 3rd. Austin may have jury duty.
- Push 2.x through that process.
- MaryKay will be out of pocket for next two weeks and unable to communicate. Lynn will be unavailable the 25th. The next PLA call will be July 9th. Communicate via the platf@lists.hl7.org in the meantime.
Adjourned 2:57 PM
Meeting Outcomes
| Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2014 Health Level Seven® International. All rights reserved
